KR20250006404A - A water-in-oil cosmetic composition comprising cell culture medium and albumin and use thereof - Google Patents
A water-in-oil cosmetic composition comprising cell culture medium and albumin and use thereof Download PDFInfo
- Publication number
- KR20250006404A KR20250006404A KR1020230085992A KR20230085992A KR20250006404A KR 20250006404 A KR20250006404 A KR 20250006404A KR 1020230085992 A KR1020230085992 A KR 1020230085992A KR 20230085992 A KR20230085992 A KR 20230085992A KR 20250006404 A KR20250006404 A KR 20250006404A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- skin
- dimethicone
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 239000006143 cell culture medium Substances 0.000 title claims abstract description 43
- 239000002537 cosmetic Substances 0.000 title claims abstract description 39
- 102000009027 Albumins Human genes 0.000 title claims abstract description 32
- 108010088751 Albumins Proteins 0.000 title claims abstract description 32
- 230000006872 improvement Effects 0.000 claims abstract description 22
- 229940008099 dimethicone Drugs 0.000 claims description 43
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 43
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 43
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 43
- 239000003921 oil Substances 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 24
- 229940024606 amino acid Drugs 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 21
- 235000014121 butter Nutrition 0.000 claims description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 229960001153 serine Drugs 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 235000002639 sodium chloride Nutrition 0.000 claims description 16
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 14
- -1 sodium biphosphate monohydrate Chemical class 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 239000002562 thickening agent Substances 0.000 claims description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 239000001993 wax Substances 0.000 claims description 11
- 230000037303 wrinkles Effects 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 9
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 9
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 9
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 9
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 9
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 9
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 9
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 8
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 8
- 230000009759 skin aging Effects 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 229940054269 sodium pyruvate Drugs 0.000 claims description 8
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 7
- 229930182816 L-glutamine Natural products 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 229930195722 L-methionine Natural products 0.000 claims description 7
- 229930182821 L-proline Natural products 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 229960003767 alanine Drugs 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 7
- 229960002429 proline Drugs 0.000 claims description 7
- 230000036548 skin texture Effects 0.000 claims description 7
- 229960002898 threonine Drugs 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000008591 skin barrier function Effects 0.000 claims description 6
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 5
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 5
- 235000013871 bee wax Nutrition 0.000 claims description 5
- 239000012166 beeswax Substances 0.000 claims description 5
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 claims description 5
- 229910000271 hectorite Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000036560 skin regeneration Effects 0.000 claims description 5
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 4
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 claims description 4
- 230000037394 skin elasticity Effects 0.000 claims description 4
- 238000005728 strengthening Methods 0.000 claims description 4
- 230000002087 whitening effect Effects 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 239000004204 candelilla wax Substances 0.000 claims description 3
- 235000013868 candelilla wax Nutrition 0.000 claims description 3
- 229940073532 candelilla wax Drugs 0.000 claims description 3
- 239000004203 carnauba wax Substances 0.000 claims description 3
- 235000013869 carnauba wax Nutrition 0.000 claims description 3
- 239000012185 ceresin wax Substances 0.000 claims description 3
- 229940102552 disteardimonium hectorite Drugs 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229940101631 quaternium-18 hectorite Drugs 0.000 claims description 3
- 229940102548 stearalkonium hectorite Drugs 0.000 claims description 3
- 235000004936 Bromus mango Nutrition 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 240000007228 Mangifera indica Species 0.000 claims description 2
- 235000014826 Mangifera indica Nutrition 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 235000009184 Spondias indica Nutrition 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 244000299461 Theobroma cacao Species 0.000 claims description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 claims description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 claims description 2
- 235000001046 cacaotero Nutrition 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000013081 microcrystal Substances 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229940094332 peg-8 dimethicone Drugs 0.000 claims description 2
- 229940088608 peg-9 polydimethylsiloxyethyl dimethicone Drugs 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 239000003760 tallow Substances 0.000 claims description 2
- 241000201895 Salicornia Species 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 24
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 65
- 235000019198 oils Nutrition 0.000 description 19
- 239000006071 cream Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229920006037 cross link polymer Polymers 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 239000000686 essence Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- 239000004909 Moisturizer Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001333 moisturizer Effects 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000003352 sequestering agent Substances 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- 229940043375 1,5-pentanediol Drugs 0.000 description 4
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940100524 ethylhexylglycerin Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 4
- 229940057874 phenyl trimethicone Drugs 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 4
- 230000021148 sequestering of metal ion Effects 0.000 description 4
- 229920002545 silicone oil Polymers 0.000 description 4
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000010696 ester oil Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 229920002379 silicone rubber Polymers 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JTSYPLOSGCFYBZ-SECBINFHSA-N (2S)-2-amino-3-(4-hydroxyphenyl)-2,3,3-triiodopropanoic acid Chemical compound IC([C@](N)(C(=O)O)I)(C1=CC=C(C=C1)O)I JTSYPLOSGCFYBZ-SECBINFHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- NPHULPIAPWNOOH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2,3-dihydroindol-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCC2=CC=CC=C12 NPHULPIAPWNOOH-UHFFFAOYSA-N 0.000 description 1
- VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 229910016870 Fe(NO3)3-9H2O Inorganic materials 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- LTKCXZGFJFAPLY-OERIEOFYSA-N [1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]azanium;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LTKCXZGFJFAPLY-OERIEOFYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000010511 apple seed oil Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229940039229 general nutrients Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 description 1
- XNCMOUSLNOHBKY-UHFFFAOYSA-H iron(3+);trisulfate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O XNCMOUSLNOHBKY-UHFFFAOYSA-H 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000010487 meadowfoam seed oil Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 235000008001 rakum palm Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 세포배양배지 및 알부민을 함유하는 피부 개선용 유중수형 화장료 조성물에 관한 것으로, 본 발명의 화장료 조성물은 세포배양배지 및 알부민을 포함하면서도 제형의 안정성을 제공함으로써, 부드럽게 펴발리며 흡수 후 끈적임 없이 영양감을 부여할 수 있는 피부 개선용 유중수형 화장료 조성물의 용도로 유용하게 사용될 수 있다. The present invention relates to a water-in-oil type cosmetic composition for skin improvement containing a cell culture medium and albumin. The cosmetic composition of the present invention provides stability of the formulation while containing a cell culture medium and albumin, and thus can be usefully used as a water-in-oil type cosmetic composition for skin improvement that can be smoothly spread and provides a feeling of nutrition without being sticky after absorption.
Description
본 발명은 세포배양배지 및 알부민을 포함하는 유중수형 화장료 조성물 및 이의 용도에 관한 것이다. The present invention relates to a water-in-oil type cosmetic composition containing a cell culture medium and albumin and its use.
피부 세포를 구성하는 세포는 동물 세포의 일종으로 각질세포(keratinocyte)와 섬유아세포(fibroblast)가 대표적이다. 상기 세포를 배양하기 위한 배지의 일반적인 조성은 DMEM(Dulbecco's Modified Eagle' s Medium) 및 소태아혈청(fetal bovine serum, FBS)을 포함한다.The cells that make up skin cells are a type of animal cell, and representative examples are keratinocytes and fibroblasts. The general composition of the medium for culturing the above cells includes DMEM (Dulbecco's Modified Eagle's Medium) and fetal bovine serum (FBS).
혈청은 성장 증진 작용, 영양분의 공급, 산화나 독소로부터 세포를 보호하는 역할을 하는 것으로 알려져 있다. 세포 배양에 있어 혈청이 배제되는 경우에는 세포 배양 자체가 거의 이루어 지지 않아 혈청은 세포의 성장 및 증식에 필수적인 성분으로 인식되고 있다. 그러나, 최근 FBS가 인간 광우병 발병의 원인이 될 수 있다고 보고된 바 있다. 이로 인해 시험자의 안전성이 위협받을 수 있고, 소태아로부터 직접 혈청을 채취하므로 동물 보호 차원에서도 문제가 될 수 있다. 또한, FBS는 고가이기 때문에 배지 가격을 상승시키는 단점이 있다.Serum is known to play a role in promoting growth, providing nutrients, and protecting cells from oxidation and toxins. When serum is excluded from cell culture, cell culture itself is hardly performed, so serum is recognized as an essential component for cell growth and proliferation. However, it has been recently reported that FBS can cause the outbreak of human mad cow disease. This can threaten the safety of the tester, and since serum is collected directly from fetal bovine fetuses, it can also be a problem in terms of animal protection. In addition, FBS is expensive, so it has the disadvantage of increasing the price of the medium.
이에, 종래 기술(대한민국 등록특허 제10-2368465호)에서는 FBS를 함유하지 않은 조성물에 대해 개시하고 있다. 그러나 상기 조성물은 염류 및 아미노산이 주성분의 대부분을 이루기 때문에 제형의 안정도에 영향을 끼치며 유중수 타입의 제형에서 수상에멀젼의 계면에 영향을 주어 입자가 깨지거나 점도가 낮아지는 문제점이 있다. Accordingly, the prior art (Korean Patent No. 10-2368465) discloses a composition that does not contain FBS. However, since the composition mainly consists of salts and amino acids, there is a problem that it affects the stability of the formulation and affects the interface of the water-in-oil type formulation, causing particle breakage or lowering of viscosity.
이러한 배경 하에, 상기 조성물의 제형의 안정도를 증진시킬 수 있는 기술을 개발하여, 본 발명을 완성하였다.Under these circumstances, a technique capable of improving the stability of the formulation of the composition was developed, thereby completing the present invention.
일 양상은 세포배양배지 및 알부민을 유효 성분으로 함유하면서 제형의 안정성이 확보된 유중수형 화장료 조성물을 제공한다.One aspect provides a water-in-oil type cosmetic composition containing a cell culture medium and albumin as active ingredients while ensuring stability of the formulation.
다른 양상은 세포배양배지 및 알부민을 유효 성분으로 함유하면서 제형의 안정성이 확보된 유중수형 피부 외용제용 조성물을 제공한다.Another aspect provides a water-in-oil type composition for external skin application containing a cell culture medium and albumin as active ingredients while ensuring stability of the formulation.
일 양상은 세포배양배지 및 알부민을 포함하는, 유중수형 (Water-in-oil, W/O) 화장료 조성물을 제공하는 것이다. One aspect is to provide a water-in-oil (W/O) cosmetic composition comprising a cell culture medium and albumin.
본 명세서에서의 용어 “세포배양배지”는 시험관 내에서(in vitro) 세포 성장 및 생존을 위해 세포가 필요로 하는 성분을 함유하거나, 세포 성장 및 생존을 돕는 성분을 함유한다. 구체적으로, 상기 성분은 비타민, 필수 또는 비필수 아미노산, 및 미량 원소를 포함하는 것일 수 있다. 상기 배지는 세포, 바람직하게는 진핵세포, 더 바람직하게는 동물 세포의 배양에 사용되는 배지일 수 있다.The term “cell culture medium” in this specification contains components required by cells for cell growth and survival in vitro, or components that help cell growth and survival. Specifically, the components may include vitamins, essential or non-essential amino acids, and trace elements. The medium may be a medium used for culturing cells, preferably eukaryotic cells, and more preferably animal cells.
상기 세포배양배지의 예로는 DMEM/F-12(Dulbecco's Modified Eagle’s Medium/Nutrient Mixture F-12), DMEM, MEMα(Minimum Essential Mediumα), BME(Basal Medium Eagle), GMEM(Glasgow Minimum Essential Medium), RPMI-1640 Medium 등이 알려져 있으나, 이에 한정되지 않는다.Examples of the above cell culture media include, but are not limited to, DMEM/F-12 (Dulbecco's Modified Eagle’s Medium/Nutrient Mixture F-12), DMEM, MEMα (Minimum Essential Mediumα), BME (Basal Medium Eagle), GMEM (Glasgow Minimum Essential Medium), RPMI-1640 Medium, etc.
또한, 본 발명의 세포배양배지는 무혈청 배지(serum-free)이다. 무혈청 배지는 인간을 포함한 동물로부터 유래된 혈청(예를 들어, 동물 유래 혈청)을 함유하지 않는 배양 배지를 의미한다. 동물 유래 혈청은 배양하고자 하는 세포의 성장을 위한 범용적인 영양분을 제공하나, 미확인된 미량 성분을 포함하므로 분석이 어렵고, 재현성 있는 시험 및 생산공정을 확립하는데 어려움이 있으며, 인체에 대한 안정성을 보장할 수 없는 문제점이 있다. 그러나 본 발명에 따른 세포배양배지는 무혈청 배지로 인체에 대한 안정성이 보장되고, 재현성 있는 시험 및 생산공정의 확립이 가능하다.In addition, the cell culture medium of the present invention is a serum-free medium. A serum-free medium means a culture medium that does not contain serum derived from animals including humans (e.g., animal-derived serum). Animal-derived serum provides general nutrients for the growth of cells to be cultured, but contains unidentified trace components, making analysis difficult, making it difficult to establish reproducible testing and production processes, and having problems in that safety to the human body cannot be guaranteed. However, the cell culture medium according to the present invention is a serum-free medium, so safety to the human body is guaranteed, and reproducible testing and production processes can be established.
또한, 상기 세포배양배지는 세포를 배양하기 전의 세포배양배지를 의미한다. 세포를 배양하기 전의 배양배지이므로, 세포배양배지의 성분의 변화가 없어 상업적으로 균질의 품질로 사용 가능하다.In addition, the above cell culture medium refers to a cell culture medium before culturing cells. Since it is a culture medium before culturing cells, there is no change in the components of the cell culture medium, so it can be used commercially with a uniform quality.
일 구현예에 있어서, 상기 세포배양배지는 아미노산 성분, 비타민 성분, 무기염 성분 및 기타 성분으로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 정제수를 추가로 포함하는 것일 수 있다.In one embodiment, the cell culture medium may include at least one selected from the group consisting of amino acid components, vitamin components, mineral salt components, and other components, and may additionally include purified water.
상기 아미노산 성분은 글리신, L-알라닌, L-발린, L-류신, L-이소류신, L-트레오닌, L-세린, L-시스테인, L-메티오닌, L-아스파르트산, L-아스파라긴, L-글루탐산, L-글루타민, L-리신, L-아르기닌, L-히스티딘, L-페닐알라닌, L-티로신, L-트립토판, L-프롤린, β-알라닌, γ-아미노부티르산, 오르니틴, 시트룰린, 호모세린, 트리요드티로신, 티록신 및 디옥시페닐알라닌으로 구성된 군으로부터 선택되는 하나 이상의 아미노산을 포함하고, 바람직하게는, 글리신, L-알라닌, L-아르기닌, L-시스테인, L-글루타민, L-히스티딘, L-라이신, L-메티오닌, L-프롤린, L-세린, L-트레오닌 및 L-발린으로 구성된 군으로부터 선택되는 하나 이상의 아미노산을 포함하는 것일 수 있다.The above amino acid component comprises at least one amino acid selected from the group consisting of glycine, L-alanine, L-valine, L-leucine, L-isoleucine, L-threonine, L-serine, L-cysteine, L-methionine, L-aspartic acid, L-asparagine, L-glutamic acid, L-glutamine, L-lysine, L-arginine, L-histidine, L-phenylalanine, L-tyrosine, L-tryptophan, L-proline, β-alanine, γ-aminobutyric acid, ornithine, citrulline, homoserine, triiodotyrosine, thyroxine and deoxyphenylalanine, and preferably, glycine, L-alanine, L-arginine, L-cysteine, L-glutamine, L-histidine, L-lysine, L-methionine, L-proline, It may comprise one or more amino acids selected from the group consisting of L-serine, L-threonine and L-valine.
상기 비타민 성분은 바이오틴, D-판토텐산칼슘, 엽산, 나이아신아미드, 피리독신 하이드로클로라이드, 리보플라빈, 티아민 하이드로클로라이드, 비타민 B12, 염화콜린, i-이노시톨 및 아스코르브산으로 구성된 군으로부터 선택되는 하나 이상의 비타민을 포함하고, 바람직하게는, i-이노시톨, 티아민 하이드로클로라이드, 나이아신아마이드 및 피리독신 하이드로클로라이드로 구성된 군으로부터 선택되는 하나 이상의 비타민을 포함하는 것일 수 있다.The above vitamin component may include at least one vitamin selected from the group consisting of biotin, D-calcium pantothenate, folic acid, niacinamide, pyridoxine hydrochloride, riboflavin, thiamine hydrochloride, vitamin B12, choline chloride, i-inositol and ascorbic acid, and preferably, at least one vitamin selected from the group consisting of i-inositol, thiamine hydrochloride, niacinamide and pyridoxine hydrochloride.
상기 무기염 성분은 염화칼슘 (CaCl2)(무수), 황산동 펜타하이드레이트(CuSO4-5H2O), 황산제이철 헵타하이드레이트(FeSO4-7H2O), 염화마그네슘(무수), 황산마그네슘(MgSO4)(무수), 염화칼륨(KCl), 염화나트륨(NaCl), 인산수소이나트륨(Na2HPO4), 인산수소나트륨 모노하이드레이트(NaH2PO4-H2O), 황산아연 헵타하이드레이트(ZnSO4-7H2O), 질산제이철 노나하이드레이트(Fe(NO3)3·9H2O) 및 탄산수소나트륨(NaHCO3)으로 구성된 군으로부터 선택되는 하나 이상의 무기염을 포함하고, 바람직하게는, 염화나트륨(NaCl), 탄산수소나트륨(NaHCO3), 염화칼륨(KCl), 염화칼슘(CaCl2)(무수) 및 인산수소나트륨 모노하이드레이트(NaH2PO4-H2O)로 구성된 군으로부터 선택되는 하나 이상의 무기염을 포함하는 것일 수 있다.The above inorganic salt component includes at least one inorganic salt selected from the group consisting of calcium chloride (CaCl 2 ) (anhydrous), copper sulfate pentahydrate (CuSO 4 -5H 2 O), ferric sulfate heptahydrate (FeSO 4 -7H 2 O), magnesium chloride (anhydrous), magnesium sulfate (MgSO 4 ) (anhydrous), potassium chloride (KCl), sodium chloride (NaCl), disodium hydrogen phosphate (Na 2 HPO 4 ), sodium hydrogen phosphate monohydrate (NaH 2 PO 4 -H 2 O), zinc sulfate heptahydrate (ZnSO 4 -7H 2 O), ferric nitrate nonahydrate (Fe(NO 3 ) 3 9H 2 O), and sodium bicarbonate (NaHCO 3 ), preferably, sodium chloride (NaCl), sodium bicarbonate (NaHCO 3 ), potassium chloride (KCl), It may contain one or more inorganic salts selected from the group consisting of calcium chloride (CaCl 2 ) (anhydrous) and sodium hydrogen phosphate monohydrate (NaH 2 PO 4 -H 2 O).
상기 기타 성분은 D-글루코즈 (덱스트로즈), 소듐 피루베이트, 히포크산틴 Na, 티미딘, 리놀레산, 리포산, 아데노신, 시티딘, 구아노신, 우리딘, 2'-데옥시아데노신, 2'-데옥시시티딘 HCl 및 2'-데옥시구아노신으로 구성된 군으로부터 선택되는 하나 이상의 기타 성분을 포함하고, 바람직하게는, 소듐 피루베이트를 포함하는 것일 수 있다.The above other components may include at least one other component selected from the group consisting of D-glucose (dextrose), sodium pyruvate, hypoxanthine Na, thymidine, linoleic acid, lipoic acid, adenosine, cytidine, guanosine, uridine, 2'-deoxyadenosine, 2'-deoxycytidine HCl and 2'-deoxyguanosine, and preferably, may include sodium pyruvate.
상기 정제수는 상기 아미노산, 비타민, 무기염 및 기타 성분을 용해시키기 위해 사용되며, 1차 이상의 증류를 거쳐 수득되거나, 필터를 통해 정제된 물일 수 있다.The purified water is used to dissolve the amino acids, vitamins, mineral salts and other ingredients, and may be water obtained through one or more distillations or purified through a filter.
일 구현예에 있어서, 상기 세포배양배지는 글리신, L-알라닌, L-아르기닌 하이드로클로라이드, L-시스테인 하이드로클로라이드-모노하이드래이트, L-글루타민, L-히스티딘 하이드로클로라이드-모노하이드래이트, L-라이신 하이드로클로라이드, L-메티오닌, L-프롤린, L-세린, L-트레오닌, L-발린, i-이노시톨, 티아민 하이드로클로라이드, 나이아신아마이드, 피리독신 하이드로클로라이드, 염화나트륨(NaCl), 탄산수소나트륨(NaHCO3), 염화칼륨(KCl), 염화칼슘(CaCl2)(무수), 인산수소나트륨 모노하이드래이트 (NaH2PO4-H2O), 및 소듐 피루베이트를 포함하는 것일 수 있으며, 구체적으로 상기 성분들로 구성되는 것일 수 있다.In one embodiment, the cell culture medium may include glycine, L-alanine, L-arginine hydrochloride, L-cysteine hydrochloride-monohydrate, L-glutamine, L-histidine hydrochloride-monohydrate, L-lysine hydrochloride, L-methionine, L-proline, L-serine, L-threonine, L-valine, i-inositol, thiamine hydrochloride, niacinamide, pyridoxine hydrochloride, sodium chloride (NaCl), sodium bicarbonate (NaHCO 3 ), potassium chloride (KCl), calcium chloride (CaCl 2 ) (anhydrous), sodium bicarbonate monohydrate (NaH 2 PO 4 -H 2 O), and sodium pyruvate, and may be specifically composed of the above components.
상기 아미노산 성분은 단백질 합성의 원료로 세포의 성장에 이용되며, 이는 세포배양배지 내에 포함된 아미노산인 세린 1 중량부를 기준으로 0.2 내지 1.2 중량부의 글리신, 0.08 내지 0.3 중량부의 L-알라닌, 2 내지 7 중량부의 L-아르기닌 하이드로클로라이드, 0.2 내지 0.9 중량부의 L-시스테인 하이드로클로라이드-모노하이드레이트, 10 내지 18 중량부의 L-글루타민, 0.8 내지 2.0 중량의 L-히스티딘 하이드로클로라이드-모노하이드레이트, 1.0 내지 5.0 중량부의 L-라이신 하이드로클로라이드, 0.2 내지 1.2 중량부의 L-메티오닌, 0.2 내지 1.2 중량부의 L-프롤린, 1.0 내지 5.0 중량부의 L-트레오닌 및 1.0 내지 5.0 중량부의 L-발린을 포함할 수 있다.The above amino acid component is used for cell growth as a raw material for protein synthesis, and it includes 0.2 to 1.2 parts by weight of glycine, 0.08 to 0.3 parts by weight of L-alanine, 2 to 7 parts by weight of L-arginine hydrochloride, 0.2 to 0.9 parts by weight of L-cysteine hydrochloride-monohydrate, 10 to 18 parts by weight of L-glutamine, 0.8 to 2.0 parts by weight of L-histidine hydrochloride-monohydrate, 1.0 to 5.0 parts by weight of L-lysine hydrochloride, 0.2 to 1.2 parts by weight of L-methionine, 0.2 to 1.2 parts by weight of L-proline, 1.0 to 5.0 parts by weight of L-threonine, and 1.0 to 5.0 parts by weight of L-valine, based on 1 part by weight of serine, an amino acid contained in a cell culture medium. Can be.
일 구현예에 있어서, 상기 세포배양배지에 포함되는 아미노산 성분 및 함량은 0.5 내지 1.0 중량부의 글리신, 0.10 내지 0.02 중량부의 L-알라닌, 5.0 내지 6.0 중량부의 L-아르기닌 하이드로클로라이드, 0.4 내지 0.7 중량부의 L-시스테인 하이드로클로라이드-모노하이드레이트, 12 내지 15 중량부의 L-글루타민, 1.0 내지 1.5 중량부의 L-히스티딘 하이드로클로라이드-모노하이드레이트, 2.0 내지 4.0 중량부의 L-리신 하이드로클로라이드, 0.4 내지 0.8 중량부의 L-메티오닌, 0.4 내지 0.8 중량부의 L-프롤린, 1.5 내지 2.5 중량부의 L-트레오닌 및 1.5 내지 2.5 중량부의 L-발린 일 수 있다. 상기 범위 내의 함량으로 아미노산 성분을 포함함으로써 세포의 성장 및 유지에 도움을 주고 제형 안정성을 향상시킬 수 있다.In one embodiment, the amino acid component and content included in the cell culture medium may be 0.5 to 1.0 parts by weight of glycine, 0.10 to 0.02 parts by weight of L-alanine, 5.0 to 6.0 parts by weight of L-arginine hydrochloride, 0.4 to 0.7 parts by weight of L-cysteine hydrochloride-monohydrate, 12 to 15 parts by weight of L-glutamine, 1.0 to 1.5 parts by weight of L-histidine hydrochloride-monohydrate, 2.0 to 4.0 parts by weight of L-lysine hydrochloride, 0.4 to 0.8 parts by weight of L-methionine, 0.4 to 0.8 parts by weight of L-proline, 1.5 to 2.5 parts by weight of L-threonine, and 1.5 to 2.5 parts by weight of L-valine. By including amino acid components in a content within the above range, it is possible to help cell growth and maintenance and improve formulation stability.
상기 세포배양배지에 있어서, 비타민 성분은 세포의 활성을 유지하는 역할을 하며, 아미노산 세린 1 중량부를 기준으로 0.2 내지 0.9 중량부의 i-이노시톨, 0.04 내지 0.8 중량부의 티아민 하이드로클로라이드, 0.04 내지 0.8 중량부의 나이아신아미드 및 0.04 내지 0.8 중량부의 피리독신 하이드로클로라이드를 포함할 수 있다.In the above cell culture medium, the vitamin component plays a role in maintaining cell activity and may include 0.2 to 0.9 parts by weight of i-inositol, 0.04 to 0.8 parts by weight of thiamine hydrochloride, 0.04 to 0.8 parts by weight of niacinamide, and 0.04 to 0.8 parts by weight of pyridoxine hydrochloride based on 1 part by weight of amino acid serine.
일 구현예에 있어서, 상기 세포배양배지에 포함되는 비타민 성분 및 함량은 아미노산 세린 1 중량부를 기준으로 0.4 내지 0.7 중량부의 i-이노시톨, 0.06 내지 0.2 중량부의 티아민 하이드로클로라이드, 0.06 내지 0.2 중량부의 나이아신아미드 및 0.06 내지 0.2 중량부의 피리독신 하이드로클로라이드일 수 있다. 상기 범위 내의 함량으로 비타민 성분을 포함함으로써 세포 활성 유지에 도움을 줄 수 있다.In one embodiment, the vitamin component and content included in the cell culture medium may be 0.4 to 0.7 parts by weight of i-inositol, 0.06 to 0.2 parts by weight of thiamine hydrochloride, 0.06 to 0.2 parts by weight of niacinamide, and 0.06 to 0.2 parts by weight of pyridoxine hydrochloride based on 1 part by weight of amino acid serine. By including the vitamin component in an amount within the above range, it may help maintain cell activity.
상기 무기염 성분은 세포 기능의 발현을 조절하는 역할을 하며, 이는 아미노산 세린 1 중량부를 기준으로 50 내지 200 중량부의 염화나트륨(NaCl), 50 내지 120 중량부의 탄산수소나트륨(NaHCO3), 2.0 내지 20 중량부의 염화칼륨(KCl), 1.0 내지 10 중량부의 염화칼슘(CaCl2)(무수) 및 0.5 내지 5.0 중량부의 인산수소나트륨 모노하이드레이트(NaH2PO4-H2O)를 포함할 수 있다.The above-mentioned inorganic salt component plays a role in regulating the expression of cell function, and may include 50 to 200 parts by weight of sodium chloride (NaCl), 50 to 120 parts by weight of sodium bicarbonate (NaHCO 3 ), 2.0 to 20 parts by weight of potassium chloride (KCl), 1.0 to 10 parts by weight of calcium chloride (CaCl 2 ) (anhydrous), and 0.5 to 5.0 parts by weight of sodium biphosphate monohydrate (NaH 2 PO 4 -H 2 O) based on 1 part by weight of amino acid serine.
일 구현예에 있어서, 상기 세포배양배지에 포함되는 무기염 성분 및 함량은 아미노산 세린 1 중량부를 기준으로 100 내지 150 중량부의 염화나트륨(NaCl), 80 내지 100 중량부의 탄산수소나트륨(NaHCO3), 8 내지 15 중량부의 염화칼륨(KCl), 2.0 내지 8.0 중량부의 염화칼슘(CaCl2)(무수) 및 1.0 내지 4.0 중량부의 인산수소나트륨 모노하이드레이트(NaH2PO4-H2O)일 수 있다.In one embodiment, the inorganic salt component and content included in the cell culture medium may be 100 to 150 parts by weight of sodium chloride (NaCl), 80 to 100 parts by weight of sodium bicarbonate (NaHCO 3 ), 8 to 15 parts by weight of potassium chloride (KCl), 2.0 to 8.0 parts by weight of calcium chloride (CaCl 2 ) (anhydrous), and 1.0 to 4.0 parts by weight of sodium biphosphate monohydrate (NaH 2 PO 4 -H 2 O) based on 1 part by weight of amino acid serine.
상기 기타 성분은 세포배양배지의 안정성 등을 향상시킬 수 있는 성분 등을 포함할 수 있으며, 이는 아미노산 세린 1 중량부를 기준으로 0.5 내지 5.0 중량부의 소듐 피루베이트를 포함할 수 있다.The above other components may include components that can improve the stability of the cell culture medium, etc., and may include 0.5 to 5.0 parts by weight of sodium pyruvate based on 1 part by weight of amino acid serine.
일 구현예에 있어서, 상기 세포배양배지에 포함되는 기타 성분 및 함량은 아미노산 세린 1 중량부를 기준으로 1.0 내지 4.0 중량부의 소듐 피루베이트일 수 있다. 상기 범위 내의 함량으로 포함되는 기타 성분은 제형 안정성을 향상시키는 등의 도움을 줄 수 있다.In one embodiment, the other components and content included in the cell culture medium may be 1.0 to 4.0 parts by weight of sodium pyruvate based on 1 part by weight of amino acid serine. Other components included in the content within the above range may help improve formulation stability, etc.
상기 조성물에 포함되는 알부민은 인간혈청 알부민 또는 소혈청 알부민일 수 있다.The albumin included in the above composition may be human serum albumin or bovine serum albumin.
상기 인간혈청 알부민은 인간 혈액에서 발견되는 혈청 알부민으로서, 인간 혈장 내에 존재하는 가장 많은 단백질이다. 본 발명에서 인간혈청 알부민은 구체적으로 재조합 인간혈청 알부민일 수 있다. 또한, 상기 소혈청 알부민은 소에서 발견되는 혈청 알부민으로서, 실험에서 단백질 농도 표준으로서 종종 사용된다.The above human serum albumin is serum albumin found in human blood and is the most abundant protein present in human plasma. In the present invention, the human serum albumin may specifically be recombinant human serum albumin. In addition, the above bovine serum albumin is serum albumin found in cattle and is often used as a protein concentration standard in experiments.
상기 알부민 함량은 10 ㎍/㎖, 50 ㎍/㎖, 100 ㎍/㎖, 200 ㎍/㎖, 300 ㎍/㎖, 500 ㎍/㎖, 1000 ㎍/㎖의 농도로 함유될 수 있다. 또는 상기 알부민 함량은 10 내지 1000 ㎍/㎖, 50 내지 500 ㎍/㎖, 100 내지 250 ㎍/㎖의 농도로 포함될 수 있다.The above albumin content may be contained in a concentration of 10 μg/ml, 50 μg/ml, 100 μg/ml, 200 μg/ml, 300 μg/ml, 500 μg/ml, 1000 μg/ml. Alternatively, the albumin content may be contained in a concentration of 10 to 1000 μg/ml, 50 to 500 μg/ml, 100 to 250 μg/ml.
상기 세포배양배지 및 알부민은 조성물 총 중량 대비 0.0001 내지 10 중량%일 수 있으며, 구체적으로 0.0001 내지 10 중량%, 0.0001 내지 5 중량%, 0.0001 내지 3 중량%, 0.0001 내지 2 중량%, 0.0001 내지 1 중량%, 0.001 내지 10 중량%, 0.001 내지 5 중량%, 0.001 내지 3 중량%, 0.001 내지 2 중량%, 0.001 내지 1 중량%, 0.01 내지 10 중량%, 0.01 내지 5 중량%, 0.01 내지 3 중량%, 0.01 내지 2 중량%, 0.01 내지 1 중량%, 0.1 내지 10 중량%, 0.1 내지 5 중량%, 0.1 내지 3 중량%, 0.1 내지 2 중량%, 0.1 내지 1 중량%, 0.25 내지 10 중량%, 0.25 내지 5 중량%, 0.25 내지 3 중량%, 0.25 내지 2 중량%, 0.25 내지 1 중량%, 0.5 내지 10 중량%, 0.5 내지 5 중량%, 0.5 내지 3 중량%, 0.5 내지 2 중량%, 0.5 내지 1 중량%, 0.75 내지 10 중량%, 0.75 내지 5 중량%, 0.75 내지 3 중량%, 0.75 내지 2 중량% 또는 0.75 내지 1 중량%로 포함되는 것일 수 있다.The above cell culture medium and albumin may be present in an amount of 0.0001 to 10 wt% based on the total weight of the composition, and specifically, 0.0001 to 10 wt%, 0.0001 to 5 wt%, 0.0001 to 3 wt%, 0.0001 to 2 wt%, 0.0001 to 1 wt%, 0.001 to 10 wt%, 0.001 to 5 wt%, 0.001 to 3 wt%, 0.001 to 2 wt%, 0.001 to 1 wt%, 0.01 to 10 wt%, 0.01 to 5 wt%, 0.01 to 3 wt%, 0.01 to 2 wt%, 0.01 to 1 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to It may be present in an amount of 3 wt%, 0.1 to 2 wt%, 0.1 to 1 wt%, 0.25 to 10 wt%, 0.25 to 5 wt%, 0.25 to 3 wt%, 0.25 to 2 wt%, 0.25 to 1 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, 0.5 to 3 wt%, 0.5 to 2 wt%, 0.5 to 1 wt%, 0.75 to 10 wt%, 0.75 to 5 wt%, 0.75 to 3 wt%, 0.75 to 2 wt%, or 0.75 to 1 wt%.
상기 화장료 조성물은 피부 상태 개선을 위한 것일 수 있다.The above cosmetic composition may be for improving skin condition.
상기 피부 상태 개선은 피부 보습, 피부 노화 개선, 피부 장벽 강화, 피부 주름 개선, 피부 탄력 증진, 피부결 개선, 피부 투명도 증진, 피부 기미 및 잡티 제거, 피부 미백 및 피부 재생으로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있다.The above skin condition improvement may include at least one selected from the group consisting of skin moisturizing, skin aging improvement, skin barrier strengthening, skin wrinkle improvement, skin elasticity enhancement, skin texture improvement, skin transparency enhancement, skin blemish and freckle removal, skin whitening, and skin regeneration.
본 명세서에서의 용어 "피부 보습"은 피부 수분을 유지하거나 수분 손실을 방지하는 모든 작용을 의미할 수 있다.The term "skin moisturizing" as used herein may mean any action that maintains skin moisture or prevents moisture loss.
본 명세서에서의 용어 "피부 노화"는 나이가 들어가면서 피부에 나타나게 되는 유형과 무형상의 변화를 통틀어 말하는 것으로, 예컨대 표피 두께가 얇아지는 현상, 진피의 세포 수나 혈관 수, DNA 손상복구 능력, 세포교체주기, 상처 회복, 피부장벽기능, 표피의 수분 유지, 땀분비, 피지분비, 비타민D 생산, 물리적 손상방어, 화학물질 제거능력, 면역반응, 감각 기능, 체온조절의 감소를 말한다. The term "skin aging" as used herein refers to a general term for tangible and intangible changes that occur in the skin with age, such as a thinning of the epidermis, a decrease in the number of cells or blood vessels in the dermis, DNA damage repair ability, cell turnover cycle, wound healing, skin barrier function, moisture retention in the epidermis, sweat secretion, sebum secretion, vitamin D production, physical damage defense, chemical removal ability, immune response, sensory function, and temperature regulation.
상기 피부 노화 개선은 외인성 요인 또는 내인성 요인에 의해 유발되는 피부 노화 개선을 의미하는 것일 수 있다. 상기 외인성 요인은 여러 가지 외부 요인, 예컨대 자외선(광)을 말하고 내인성 요인은 연대기적 요인이라고도 지칭되며 주로 시간의 흐름에 의해 발생하는 요인을 말한다. 즉, 상기 피부 노화는 구체적으로는 자외선, 공해, 담배연기, 화학물질 등에 의한 외부 자극에 의해 유도되는 조기 노화 증상 뿐만 아니라, 나이가 들어감에 의해 피부세포의 증식이 감소함에 따라 발생하는 자연노화 현상을 포함하며 주름, 탄력 감소, 피부 쳐짐 및 건조 현상 등을 모두 포함하는 개념이다. 또한 주름은 내ㆍ외부 요인의 변화에 의한 자극이 피부조직을 구성하고 있는 성분을 변화시켜 주름을 유발하는 것을 포함한다.The above skin aging improvement may mean skin aging improvement caused by exogenous factors or endogenous factors. The exogenous factors refer to various external factors, such as ultraviolet rays (light), and the endogenous factors are also referred to as chronological factors and mainly refer to factors that occur due to the passage of time. That is, the skin aging includes not only premature aging symptoms induced by external stimuli such as ultraviolet rays, pollution, cigarette smoke, and chemicals, but also natural aging phenomena that occur as skin cell proliferation decreases with age, and is a concept that includes wrinkles, loss of elasticity, sagging skin, and dryness. In addition, wrinkles include stimuli caused by changes in internal and external factors that change the components that make up skin tissue, thereby causing wrinkles.
상기 노화는 광노화일 수 있다. 상기 용어 "광노화(Photoaging)"는 외부 환경적인 요인에 의해 유발되는 현상으로, 가장 대표적인 인자로는 자외선이 있다. 자외선은 단백질 분해효소의 활성화와 기질단백질의 사슬절단 및 비정상적인 교차결합 등의 생체 구성 성분들의 손상을 가져오고, 이러한 메커니즘의 반복은 외관상으로도 확연한 피부노화를 초래하게 된다.The above aging may be photoaging. The above term "photoaging" is a phenomenon caused by external environmental factors, the most representative of which is ultraviolet rays. Ultraviolet rays cause damage to biological components such as activation of proteolytic enzymes, chain cleavage of substrate proteins, and abnormal cross-linking, and repetition of this mechanism causes skin aging that is evident in appearance.
본 명세서에서의 용어 "피부 장벽 강화"는 피부 가장 바깥쪽에 위치하여 수분과 영양 손실을 막아주는 피부 장벽의 기능이 증진되는 모든 작용을 의미할 수 있다.The term "strengthening skin barrier" in this specification may mean any action that enhances the function of the skin barrier, which is located at the outermost part of the skin and prevents moisture and nutrient loss.
본 명세서에서 용어 "주름"은 피부의 탄력성이 상실되어 느슨해진 상태를 의미하며, 예를 들면 피부가 접히는 것일 수 있다. 상기 "피부 주름 예방 또는 개선"이란 주름과 관련된 인자의 발현을 억제하여 주름을 방지 또는 개선하거나, 콜라겐 총량을 증가시키는 모든 작용을 의미할 수 있다.The term "wrinkle" in this specification means a state in which skin loses elasticity and becomes loose, and may be, for example, skin folding. The above "prevention or improvement of skin wrinkles" may mean any action that prevents or improves wrinkles by suppressing the expression of factors related to wrinkles, or increases the total amount of collagen.
본 명세서에서 용어 "피부 투명도"는 피부 표면에서의 입사광에 대한 투과광의 비율을 의미한다. 입사광이 피부 표면에서 산란되어 일부 흩어진 후 나머지가 피부 내부로 투과되고, 투과된 빛 (투과광)이 피부 내부에서 다시 반사되어 나오게 된다. 피부 내부에서 반사되어 나오는 빛 (확산 반사)의 양이 증가할수록 피부 투명도는 증가한다.The term "skin transparency" in this specification means the ratio of transmitted light to incident light at the skin surface. After some of the incident light is scattered and dispersed at the skin surface, the remainder is transmitted into the skin, and the transmitted light (transmitted light) is reflected back out from inside the skin. As the amount of light reflected from inside the skin (diffuse reflection) increases, skin transparency increases.
본 명세서에서의 용어 "피부 탄력 증진"이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것을 의미한다.The term "improving skin elasticity" as used herein means alleviating the degree of sagging or loosening of the skin.
본 명세서에서의 용어 "피부결(skin microrelief)"은 피부 표면의 미세한 선에 의해 형성된 3차원 미세구조를 의미한다. 탄력, 주름, 보습 등과는 별개로 피부 상태의 지표가 되는 것으로, 보다 구체적으로 피부결은 노화가 시작되기 전에 노화를 감지할 수 있는 노화의 신뢰성 있는 지표가 된다. 아울러, 피부결은 단순히 거칠고 매끄러운 피부 표면의 상태가 아닌 피부 속 상태를 반영하는 것으로서, 겉으로 보이는 피부 표면의 피부결은 피부 전체 구조체에서 밖으로 드러난 일부분일 뿐, 피부결이 손상되었다는 것은 피부속 변화가 반영된 것이다.The term "skin microrelief" in this specification refers to a three-dimensional microstructure formed by fine lines on the skin surface. It is an indicator of skin condition separately from elasticity, wrinkles, and moisture, and more specifically, skin texture is a reliable indicator of aging that can detect aging before aging begins. In addition, skin texture is not simply a rough and smooth skin surface condition, but rather reflects the condition inside the skin, and the skin texture of the visible skin surface is only a part of the entire skin structure that is revealed outside, and damage to the skin texture reflects changes inside the skin.
본 명세서에서의 용어 "피부 재생"은 피부의 일부분이 소실되었을 경우 그 부분을 보충하거나 피부 세포의 증식을 증진시키는 모든 작용을 의미할 수 있다. 구체적으로, 피부 재생은 피부 상처 부위의 피부조직의 재생을 의미할 수 있다.The term "skin regeneration" in this specification may mean any action that replenishes a portion of the skin that has been lost or promotes the proliferation of skin cells. Specifically, skin regeneration may mean the regeneration of skin tissue at a site of a skin wound.
본 명세서에서 용어 "피부 미백"은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 의미할 수 있다.The term "skin whitening" in this specification may mean not only brightening the skin tone by inhibiting the synthesis of melanin pigment, but also improving skin hyperpigmentation such as blemishes or freckles caused by ultraviolet rays, hormones, or genetics.
본 명세서에서의 용어 "잡티"는 노화에 수반되는 각질층의 비후에 의한 탁함 또는 음영, 피부의 붉은 빛 저하, 색소의 침착, 피부의 탄력 저하, 피부의 황색화, 땀이나 피지 등의 오염과 같은 다양한 요인이 서로 복합적으로 관여하여 발생한다고 추측되고 있다.The term "freckle" in this specification is thought to be caused by a complex interplay of various factors, such as cloudiness or shade due to thickening of the stratum corneum accompanying aging, decreased redness of the skin, deposition of pigments, decreased elasticity of the skin, yellowing of the skin, and contamination with sweat or sebum.
상기 화장료 조성물은 피부 상태 개선 효율이 증진된 것일 수 있으며, 구체적으로 세포배양배지 및/또는 알부민을 유효 성분으로 포함하지 않는 조성물과 비교하여 피부 상태 개선 효율이 증진된 것일 수 있다.The above cosmetic composition may have enhanced skin condition improvement efficiency, and specifically, may have enhanced skin condition improvement efficiency compared to a composition that does not contain a cell culture medium and/or albumin as active ingredients.
구체적으로, 상기 화장료 조성물의 피부 상태 개선 효율은 세포배양배지 및/또는 알부민을 유효 성분으로 포함하지 않는 조성물과 비교하여, 10% 이상, 30% 이상, 50% 이상, 70% 이상, 100% 이상, 150% 이상, 200% 이상 또는 300% 이상 증진된 것일 수 있으며, 구체적으로 10% 내지 300%, 10% 내지 200%, 10% 내지 150%, 10% 내지 100%, 10% 내지 70%, 10% 내지 50%, 30% 내지 300%, 30% 내지 200%, 30% 내지 150%, 30% 내지 100%, 30% 내지 70%, 30% 내지 50%, 50% 내지 300%, 50% 내지 200%, 50% 내지 150%, 50% 내지 100% 또는 50% 내지 70% 증진된 것일 수 있다.Specifically, the skin condition improvement efficiency of the cosmetic composition may be enhanced by 10% or more, 30% or more, 50% or more, 70% or more, 100% or more, 150% or more, 200% or more, or 300% or more, compared to a composition that does not contain a cell culture medium and/or albumin as an active ingredient, and specifically, by 10% to 300%, 10% to 200%, 10% to 150%, 10% to 100%, 10% to 70%, 10% to 50%, 30% to 300%, 30% to 200%, 30% to 150%, 30% to 100%, 30% to 70%, 30% to 50%, 50% to 300%, 50% to 200%, It can be enhanced by 50% to 150%, 50% to 100%, or 50% to 70%.
상기 유중수형 조성물은 계면활성제, 왁스, 버터, 점증제(안정화제), 고급 알코올 및 고급 지방산으로 구성된 군에서 선택된 하나 이상을 추가로 포함하는 것일 수 있다.The above-mentioned water-in-oil composition may additionally contain at least one selected from the group consisting of a surfactant, a wax, a butter, a thickener (stabilizer), a higher alcohol, and a higher fatty acid.
일 구현예에 있어서, 상기 유중수형 조성물은 세포배양배지, 알부민, 계면활성제, 왁스, 및 점증제(안정화제)를 포함하는 것일 수 있다.In one embodiment, the water-in-oil composition may include a cell culture medium, albumin, a surfactant, a wax, and a thickening agent (stabilizer).
상기 계면활성제는 피이지-8 다이메티콘, 피이지-9 폴리디메틸실록시에틸다이메티콘, 피이지-10 다이메티콘, 피이지-12 다이메티콘, 피이지-11 메틸이서 다이메티콘, 세틸피이지/피피지 다이메티콘, 세틸피이지/피피지-10/1 다이메티콘, 비스-피이지/피피지-14/14 다이메티콘, 비스-피이지/피피지-20/20 다이메티콘, 피이지/피피지-18/18다이메티콘, 피이지/피피지-19/19 다이메티콘, 피이지/피피지-20/20 다이메티콘, 폴리글리세릴-3 폴리디메틸실록시에틸 다이메티콘, 라우릴 폴리글리세릴-3 폴리디메틸실록시에틸 다이메티콘, 및 라우릴 피이지-9 폴리디메틸실록시에틸다이메티콘로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above surfactants are PEG-8 dimethicone, PEG-9 polydimethylsiloxyethyl dimethicone, PEG-10 dimethicone, PEG-12 dimethicone, PEG-11 methyl ether dimethicone, cetyl PEG/PPG dimethicone, cetyl PEG/PPG-10/1 dimethicone, bis-PEG/PPG-14/14 dimethicone, bis-PEG/PPG-20/20 dimethicone, PEG/PPG-18/18 dimethicone, PEG/PPG-19/19 dimethicone, PEG/PPG-20/20 dimethicone, polyglyceryl-3 polydimethylsiloxyethyl dimethicone, lauryl polyglyceryl-3 polydimethylsiloxyethyl dimethicone, and lauryl PEG-9. It may include at least one selected from the group consisting of, but is not limited to, polydimethylsiloxyethyl dimethicone.
상기 계면활성제는 조성물 총 중량 대비 0.01 내지 10 중량%일 수 있으며, 구체적으로 0.01 내지 10 중량%, 0.01 내지 5 중량%, 0.01 내지 4 중량%, 0.01 내지 3 중량%, 0.01 내지 2 중량%, 0.01 내지 1 중량%, 0.1 내지 10 중량%, 0.1 내지 5 중량%, 0.1 내지 4 중량%, 0.1 내지 3 중량%, 0.1 내지 2 중량%, 0.1 내지 1 중량%, 0.5 내지 10 중량%, 0.5 내지 5 중량%, 0.5 내지 4 중량%, 0.5 내지 3 중량%, 0.5 내지 2 중량%, 0.5 내지 1 중량%, 1 내지 10 중량%, 1 내지 5 중량%, 1 내지 4 중량%, 1 내지 3 중량%, 1 내지 2 중량%, 2 내지 10 중량%, 2 내지 5 중량%, 2 내지 4 중량%, 2 내지 3 중량%, 3 내지 10 중량%, 3 내지 5 중량% 또는 3 내지 4 중량% 로 포함되는 것일 수 있다.The surfactant may be present in an amount of 0.01 to 10 wt% based on the total weight of the composition, and specifically, 0.01 to 10 wt%, 0.01 to 5 wt%, 0.01 to 4 wt%, 0.01 to 3 wt%, 0.01 to 2 wt%, 0.01 to 1 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 4 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, 0.5 to 4 wt%, 0.5 to 3 wt%, 0.5 to 2 wt%, 0.5 to 1 wt%, 1 to 10 wt%, 1 to 5 wt%, 1 to 4 wt%, 1 to It may be comprised in an amount of 3 wt%, 1 to 2 wt%, 2 to 10 wt%, 2 to 5 wt%, 2 to 4 wt%, 2 to 3 wt%, 3 to 10 wt%, 3 to 5 wt% or 3 to 4 wt%.
상기 왁스는 비즈왁스, 칸데릴라왁스, 카나우바왁스, 멀티왁스, 파라핀왁스, 마이크로크리스탈 왁스 및 세레신 왁스로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above wax may include at least one selected from the group consisting of beeswax, candelilla wax, carnauba wax, multiwax, paraffin wax, microcrystal wax and ceresin wax, but is not limited thereto.
상기 왁스는 조성물 총 중량 대비 0.01 내지 10 중량%일 수 있으며, 구체적으로 0.01 내지 10 중량%, 0.01 내지 5 중량%, 0.01 내지 4 중량%, 0.01 내지 3 중량%, 0.01 내지 2 중량%, 0.01 내지 1.5 중량%, 0.01 내지 1 중량%, 0.1 내지 10 중량%, 0.1 내지 5 중량%, 0.1 내지 4 중량%, 0.1 내지 3 중량%, 0.1 내지 2 중량%, 0.1 내지 1.5 중량%, 0.1 내지 1 중량%, 0.5 내지 10 중량%, 0.5 내지 5 중량%, 0.5 내지 4 중량%, 0.5 내지 3 중량%, 0.5 내지 2 중량%, 0.5 내지 1.5 중량%, 0.5 내지 1 중량%, 1 내지 10 중량%, 1 내지 5 중량%, 1 내지 4 중량%, 1 내지 3 중량%, 1 내지 2 중량% 또는 1 내지 1.5 중량%로 포함되는 것일 수 있다.The wax may be present in an amount of 0.01 to 10 wt% based on the total weight of the composition, and specifically, 0.01 to 10 wt%, 0.01 to 5 wt%, 0.01 to 4 wt%, 0.01 to 3 wt%, 0.01 to 2 wt%, 0.01 to 1.5 wt%, 0.01 to 1 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 4 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1.5 wt%, 0.1 to 1 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, 0.5 to 4 wt%, 0.5 to 3 wt%, 0.5 to 2 wt%, 0.5 to 1.5 wt%, 0.5 It may be included at 1 wt%, 1 to 10 wt%, 1 to 5 wt%, 1 to 4 wt%, 1 to 3 wt%, 1 to 2 wt% or 1 to 1.5 wt%.
상기 점증제는 연속상의 점도 조절 목적 및 안정화제로서, 헥토라이트, 쿼터늄-18헥토라이트, 스테아랄코늄헥토라이트 및 다이스테아다이모늄헥토라이트로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above thickener may include at least one selected from the group consisting of hectorite, quaternium-18 hectorite, stearalkonium hectorite, and disteardimonium hectorite, as a viscosity control agent and stabilizer of the continuous phase, but is not limited thereto.
상기 점증제(안정화제)는 조성물 총 중량 대비 0.01 내지 10 중량%일 수 있으며, 구체적으로 0.01 내지 10 중량%, 0.01 내지 5 중량%, 0.01 내지 4 중량%, 0.01 내지 3 중량%, 0.01 내지 2 중량%, 0.01 내지 1.5 중량%, 0.01 내지 1 중량%, 0.1 내지 10 중량%, 0.1 내지 5 중량%, 0.1 내지 4 중량%, 0.1 내지 3 중량%, 0.1 내지 2 중량%, 0.1 내지 1.5 중량%, 0.1 내지 1 중량%, 0.5 내지 10 중량%, 0.5 내지 5 중량%, 0.5 내지 4 중량%, 0.5 내지 3 중량%, 0.5 내지 2 중량%, 0.5 내지 1.5 중량%, 0.5 내지 1 중량%, 1 내지 10 중량%, 1 내지 5 중량%, 1 내지 4 중량%, 1 내지 3 중량%, 1 내지 2 중량% 또는 1 내지 1.5 중량%로 포함되는 것일 수 있다.The thickener (stabilizer) may be present in an amount of 0.01 to 10 wt% based on the total weight of the composition, and specifically, 0.01 to 10 wt%, 0.01 to 5 wt%, 0.01 to 4 wt%, 0.01 to 3 wt%, 0.01 to 2 wt%, 0.01 to 1.5 wt%, 0.01 to 1 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 4 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1.5 wt%, 0.1 to 1 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, 0.5 to 4 wt%, 0.5 to 3 wt%, 0.5 to 2 wt%, 0.5 to It may be present in an amount of 1.5 wt%, 0.5 to 1 wt%, 1 to 10 wt%, 1 to 5 wt%, 1 to 4 wt%, 1 to 3 wt%, 1 to 2 wt% or 1 to 1.5 wt%.
상기 버터는 시어버터, 망고씨버터, 카카오씨버터, 쿠푸아수씨버터, 야자씨버터, 트라이키리아이메티카씨버터, 코쿰씨버터, 보르네오탈로우씨버터 및 사라수씨버터로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above butter may include at least one selected from the group consisting of shea butter, mango seed butter, cacao seed butter, cupuacu seed butter, palm seed butter, triciriaimetica seed butter, kokum seed butter, borneo tallow seed butter and sala seed butter, but is not limited thereto.
상기 고급 알코올은 세틸알코올, 스테아릴알코올, 베헤닐알코올, 및 바틸알코올로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above higher alcohol may include at least one selected from the group consisting of cetyl alcohol, stearyl alcohol, behenyl alcohol, and batyl alcohol, but is not limited thereto.
상기 고급 지방산은 스테아릭애씨드, 이소스테아릭애씨드, 미리스틱애씨드 및 팔미틱애씨드로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above-mentioned higher fatty acids may include at least one selected from the group consisting of stearic acid, isostearic acid, myristic acid and palmitic acid, but are not limited thereto.
상기 화장료 조성물은 상기 기재된 성분 외에 오일 및/또는 실리콘계 엘라스토머를 더 포함할 수 있다.The above cosmetic composition may further contain oil and/or silicone-based elastomer in addition to the ingredients described above.
상기 오일은 화장품에 통상 사용되는 오일이라면 그 종류를 제한하지 않는다. 예를 들어, 상기 오일은 에스테르계 오일, 탄화수소계 오일, 실리콘계 오일, 식물성 오일, 및 트리글리세리드로 이루어진 군으로부터 선택된 1종 이상일 수 있다.The above oil is not limited to a type as long as it is an oil commonly used in cosmetics. For example, the above oil may be at least one selected from the group consisting of ester oil, hydrocarbon oil, silicone oil, vegetable oil, and triglyceride.
상기 에스테르계 오일은 지방산과 지방 알코올의 에스테르 화합물일 수 있다. 예를 들어, 상기 에스테르계 오일은 이소프로필 미리스테이트 (Isopropyl Myristate), 이소프로필 팔미테이트 (Isopropyl Palmitate), 에틸헥실팔미테이트(Ethylhexyl palmitate), 세틸 옥타노에이트 (Cetyl Octanoate), 세틸 2-에틸 헥사노에이트 (Cetyl 2-Ethyl Hexanoate), 2-옥틸 도데실 미리스테이트 (2-Octyl Dodecyl Myristate), 디-이소스테아릴 말레이트 (Di-isostearyl Malate) 등을 포함할 수 있다.The above ester oil may be an ester compound of a fatty acid and a fatty alcohol. For example, the ester oil may include isopropyl myristate, isopropyl palmitate, ethylhexyl palmitate, cetyl octanoate, cetyl 2-ethyl hexanoate, 2-octyl dodecyl myristate, di-isostearyl malate, and the like.
상기 탄화수소계 오일은 유동파라핀, 바세린, 이소파라핀류 등의 석유계 오일; 하이드로제네이티드폴리데센, 합성 스쿠알란, 폴리부텐 등의 합성계 오일; 식물성의 스쿠알란, 수소 첨가한 스쿠알란 등의 식물계 오일 등을 포함할 수 있다.The above hydrocarbon oil may include petroleum oils such as liquid paraffin, petrolatum, and isoparaffin; synthetic oils such as hydrogenated polydecene, synthetic squalane, and polybutene; and plant oils such as vegetable squalane and hydrogenated squalane.
상기 실리콘계 오일은 실록산 결합 (Siloxane bond, Si-O-Si)을 갖는 오일일 수 있다. 예를 들어, 상기 실리콘계 오일은 디메티콘 (Dimethicone), 디메티콘올 (Dimethiconol), 페닐트라이메티콘 (Phenyl Trimethicone), 디실록세인 (Disiloxane), 사이클로메티콘(Cyclomethicone), 사이클로펜타실록세인(Cyclopentasiloxane), 사이클로헥사실록세인(Cyclohexasiloxane) 등을 포함할 수 있다.The silicone oil may be an oil having a siloxane bond (Si-O-Si). For example, the silicone oil may include dimethicone, dimethiconol, phenyl trimethicone, disiloxane, cyclomethicone, cyclopentasiloxane, cyclohexasiloxane, and the like.
상기 식물성 오일은 자연계에 존재하는 식물로부터 얻은 오일일 수 있다. 예를 들어, 상기 식물성 오일은 올리브오일, 메도우폼씨오일, 로즈힙열매오일, 아보카도오일, 동백오일, 사과씨오일, 포도씨오일, 해바라기씨오일, 마카다미아넛오일, 코코넛오일, 피마자유, 호호바씨오일, 카프릴릭/카프릭트리글리세리드 등을 포함할 수 있다.The above vegetable oil may be an oil obtained from a plant existing in nature. For example, the above vegetable oil may include olive oil, meadowfoam seed oil, rosehip fruit oil, avocado oil, camellia oil, apple seed oil, grape seed oil, sunflower seed oil, macadamia nut oil, coconut oil, castor oil, jojoba seed oil, caprylic/capric triglyceride, etc.
상기 실리콘계 엘라스토머는 실리콘 가교물을 실리콘 오일 및 각종 오일류에 팽윤시킨 물질을 의미할 수 있다. 상기 실리콘계 엘라스토머는 실리콘계 크로스폴리머를 포함할 수 있다. 상기 실리콘계 크로스폴리머는 다이메티콘 크로스폴리머, 비닐다이메티콘 크로스폴리머 등을 포함할 수 있으나, 이에 제한되지 않는다. 상기 실리콘계 엘라스토머는 다이메티콘/비닐다이메티콘 크로스폴리머를 포함할 수 있다.The above silicone elastomer may refer to a material in which a silicone cross-linked product is swelled in silicone oil and various oils. The silicone elastomer may include a silicone crosspolymer. The silicone crosspolymer may include, but is not limited to, a dimethicone crosspolymer, a vinyl dimethicone crosspolymer, and the like. The silicone elastomer may include a dimethicone/vinyl dimethicone crosspolymer.
상기 화장료 조성물은 상기 기재된 성분 외에 정제수, 보습제, pH조절제, 금속이온봉쇄제, 및/또는 방부제 등을 더 포함할 수 있다.The above cosmetic composition may further include purified water, a moisturizer, a pH regulator, a metal ion sequestering agent, and/or a preservative in addition to the ingredients described above.
상기 방부제는 프로판다이올, 에틸헥실글리세린, 1,2-헥산디올 및 펜틸렌글라이콜로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above preservative may include, but is not limited to, one or more selected from the group consisting of propanediol, ethylhexylglycerin, 1,2-hexanediol, and pentylene glycol.
상기 보습제는 글리세린을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above moisturizer may include, but is not limited to, glycerin.
상기 금속이온봉쇄제는 다이소듐이디티에이을 포함하는 것일 수 있으며, 이에 제한되는 것은 아니다.The above metal ion sequestering agent may include, but is not limited to, disodium EDTA.
일 구현예에 있어서, 상기 화장료 조성물은 1) 세포배양배지 및 알부민을 포함하는 수상부; 및 2) 점증제(안정화제), 계면활성제 및 왁스로 구성된 군에서 선택된 하나 이상을 포함하는 유상부를 포함하는, 유중수형 화장료 조성물일 수 있다.In one embodiment, the cosmetic composition may be a water-in-oil type cosmetic composition comprising 1) an aqueous portion including a cell culture medium and albumin; and 2) an oily portion including at least one selected from the group consisting of a thickener (stabilizer), a surfactant, and a wax.
상기 화장료 조성물의 수상부는 정제수, 금속이온봉쇄재, 보습제 및 방부제로 구성된 군에서 선택된 하나 이상을 추가로 포함하는 것일 수 있다.The aqueous portion of the above cosmetic composition may additionally include at least one selected from the group consisting of purified water, a metal ion sequestering agent, a moisturizer, and a preservative.
상기 화장료 조성물의 유상부는 오일 및 실리콘계 엘라스토머로 구성된 군에서 선택된 하나 이상을 추가로 포함하는 것일 수 있다.The oily portion of the above cosmetic composition may additionally include at least one selected from the group consisting of oil and silicone-based elastomer.
상기 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 스킨류, 로션류, 에센스류, 크림류, 팩류, 파운데이션류, 패치류, 헤어토닉류, 마이크로 니들 패치류 및 메이크업베이스류 중 선택된 어느 하나의 제형을 가질 수 있으나, 이에 제한되지 않을 수 있다.The above cosmetic composition may be manufactured in any formulation commonly manufactured in the art. For example, it may have any formulation selected from among skin products, lotions, essences, creams, packs, foundations, patches, hair tonics, micro needle patches, and makeup bases, but may not be limited thereto.
상기 화장료 조성물 제형의 일 예로서, 유연화장수, 수렴화장수, 영양화장수, 로션, 젤, 크림, 에센스, 아이에센스, 아이크림, 영양크림, 마사지크림, 클레이형 팩, 마스크팩을 포함하는 스킨케어 제품, 립스틱, 립틴트, 립글로스, 립 펜슬, 아이섀도우, 파운데이션, 파우더, 컨실러, 아이라이너, 아이섀도우, 마스카라를 포함하는 메이크업제품, 아이리무버, 메이크업리무버, 클렌징폼, 클렌징 크림, 클렌징 오일, 클렌징 워터, 손 소독제, 핸드워시, 핸드 스크럽, 바디 워시, 바디 스크럽, 쉐이빙 로션, 비누, 물티슈를 포함하는 세정제품, 바디로션, 바디오일, 바디 미스트, 바디에센스, 핸드크림, 풋크림, 왁스형 제모제을 포함하는 바디케어제품, 베이비 로션, 베이비 크림, 기저귀 발진 크림을 포함하는 유아화장품, 선크림, 선 스틱, 선 스프레이, 인공 태닝 제품을 포함하는 선케어제품, 샴푸, 린스, 헤어 컨디셔너 크림, 헤어스타일링 젤, 폼, 헤어 무스, 헤어 스프레이, 스타일링 로션, 스타일링 크림, 헤어에센스, 모발 염료, 모발 탈색 크림, 컬 활성제 겔을 포함하는 헤어제품, 매니큐어, 네일폴리쉬, 큐티클 리무버, 큐티클 크림를 포함하는 네일케어제품, 치약, 구강청결제, 구강 린스, 구강 필름, 검을 포함하는 퍼스널케어제품, 향수, 식물추출물, 소취제 및 지한제 제형으로 제조될 수도 있다.As an example of the above cosmetic composition formulation, skin care products including a softening toner, an astringent toner, a nourishing toner, a lotion, a gel, a cream, an essence, an eye essence, an eye cream, a nourishing cream, a massage cream, a clay pack, and a mask pack, makeup products including a lipstick, a lip tint, a lip gloss, a lip pencil, an eye shadow, a foundation, a powder, a concealer, an eyeliner, an eye shadow, and a mascara, eye removers, makeup removers, cleansing foams, cleansing creams, cleansing oils, cleansing water, hand sanitizers, hand wash, hand scrubs, body wash, body scrubs, shaving lotions, soaps, and cleaning products including wet tissues, body care products including a body lotion, a body oil, a body mist, a body essence, a hand cream, a foot cream, and a wax-type hair removal agent, infant cosmetics including a baby lotion, a baby cream, and a diaper rash cream, sunscreens, sun sticks, Sun care products including sun sprays, artificial tanning products, hair products including shampoos, rinses, hair conditioner creams, hair styling gels, foams, hair mousses, hair sprays, styling lotions, styling creams, hair essences, hair dyes, hair bleaching creams, curl activator gels, nail care products including nail polishes, cuticle removers, cuticle creams, toothpaste, mouthwashes, mouth rinses, mouth films, personal care products including gums, perfumes, plant extracts, deodorants, and antiperspirant formulations.
일 구현예에 있어서, 상기 화장료 조성물은 O/W(유중수) 에멀전 제형일 수 있다. 본 발명의 화장료 조성물은, 예를 들어 액상 제품, 로션, 에센스, 크림, 선로션, 선크림, 메이크업 베이스, 파운데이션, 비비크림, 스틱상 제품 또는 밤(Balm) 타입 제품 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 또한, 제조하고자 하는 제형에 따라 추가로 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 방부제, 향료 등을 선택하여 배합 첨가할 수 있다. 또한 자외선 차단제, 광산란제 등을 포함할 수 있으며, 그 제형 및 첨가성분이 상기 내용에 한정되는 것은 아니다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.In one embodiment, the cosmetic composition may be an O/W (water-in-oil) emulsion formulation. The cosmetic composition of the present invention may be formulated as, for example, a liquid product, a lotion, an essence, a cream, a sun lotion, a sunscreen, a makeup base, a foundation, a BB cream, a stick product, or a balm-type product, but is not limited thereto. In addition, depending on the formulation to be manufactured, oil, water, a surfactant, a moisturizer, a lower alcohol, a thickener, a chelating agent, a preservative, a fragrance, etc. may be additionally selected and mixed and added. In addition, a UV blocker, a light scattering agent, etc. may be included, and the formulation and added ingredients are not limited to the above contents. In addition, the ingredients may be introduced in an amount generally used in the field of dermatology.
상기 화장료 조성물은 화장품에 통상 사용되는 추가 성분, 예컨대, 안정화제, 용매화제, 점증제, 분산제, 향료, 충전제, 보존제, 중성화제, 감미료, 비타민, 항산화제 및 금속 이온 봉쇄제와 같은 통상적인 보조제를 포함할 수 있다. 당업자는 본 명세서에 따른 조성물의 유리한 특성이 예상된 첨가에 의해 악영향을 받지 않거나 실질적으로 받지 않도록, 임의의 추가 성분 및/또는 이의 양을 선택할 수 있다.The above cosmetic composition may contain additional ingredients commonly used in cosmetics, such as conventional adjuvants such as stabilizers, solvators, thickeners, dispersants, fragrances, fillers, preservatives, neutralizers, sweeteners, vitamins, antioxidants and metal ion sequestering agents. A person skilled in the art can select any additional ingredient and/or its amount such that the advantageous properties of the composition according to the present disclosure are not or are substantially not adversely affected by the expected addition.
다른 양상은 세포배양배지 및 알부민을 포함하는, 유중수형 피부 외용제 조성물을 제공하는 것이다. 상기에서 설명한 내용과 동일한 부분은 상기 조성물에도 공히 적용된다.Another aspect is to provide a water-in-oil type external skin composition comprising a cell culture medium and albumin. The same parts as described above are also applied to the composition.
상기 피부 외용제 조성물은 피부 상태 개선을 위한 것일 수 있다.The above skin external composition may be for improving skin condition.
상기 피부 상태 개선은 피부 보습, 피부 노화 개선, 피부 장벽 강화, 피부 주름 개선, 피부 탄력 증진, 피부결 개선, 피부 투명도 증진, 피부 기미잡티 제거, 피부 미백 및 피부 재생으로 구성된 군에서 선택된 하나 이상을 포함하는 것일 수 있다.The above skin condition improvement may include at least one selected from the group consisting of skin moisturizing, skin aging improvement, skin barrier strengthening, skin wrinkle improvement, skin elasticity enhancement, skin texture improvement, skin transparency enhancement, skin blemish removal, skin whitening, and skin regeneration.
상기 피부 외용제 조성물은 크림, 겔, 연고, 피부 유화제, 피부 현탁액, 경피전달성 패치, 약물 함유 붕대, 로션, 또는 그 조합일 수 있다. 각 제형에 의한 피부 외용제 조성물은 본 발명의 조성물 이외의 다른 성분들을 기타 피부 외용제의 제형 또는 사용 목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 이 경우 다른 원료와 동시에 적용 할 경우 상승효과가 일어날 수 있다.The above skin external composition may be a cream, a gel, an ointment, a skin emulsifier, a skin suspension, a transdermal delivery patch, a drug-containing bandage, a lotion, or a combination thereof. The skin external composition according to each formulation can be appropriately selected and mixed by a person skilled in the art according to the formulation or purpose of use of other skin external compositions, etc., in addition to the composition of the present invention, without difficulty, and in this case, a synergistic effect may occur when applied simultaneously with other raw materials.
상기 피부 외용제는 통상 화장품이나 의약품 등의 피부외용제에 사용되는 성분, 예를 들면 수성성분, 유성성분, 분말성분, 알코올류, 보습제, 증점제, 자외선흡수제, 미백제, 방부제, 산화방지제, 계면활성제, 향료, 색제, 각종 피부 영양제, 또는 이들의 조합과 필요에 따라서 적절하게 배합될 수 있다.The above skin external preparation may be appropriately mixed with ingredients commonly used in skin external preparations such as cosmetics or medicines, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof, as needed.
상기 피부외용제는, 에데트산이나트륨, 에데트산삼나트륨, 시트르산나트륨, 폴리인산나트륨, 메타인산나트륨, 글루콘산 등의 금속봉쇄제, 카페인, 탄닌, 벨라파밀, 감초추출물, 글라블리딘, 칼린의 과실의 열수추출물, 각종생약, 아세트산토코페롤, 글리틸리틴산, 트라넥삼산 및 그 유도체 또는 그 염등의 약제, 비타민 C, 아스코르브산인산마그네슘, 아스코르브산글루코시드, 알부틴, 코지산, 글루코스, 프룩토스, 트레할로스 등의 당류 등도 적절하게 배합할 수 있다.The above skin external preparation may also appropriately contain metal sequestering agents such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannin, bellapamil, licorice extract, glablidine, hot water extract of the fruit of Kalin, various crude drugs, tocopheryl acetate, glycyrrhizic acid, tranexamic acid and derivatives or salts thereof; and drugs such as vitamin C, magnesium ascorbic acid phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.
본 발명은 세포배양배지 및 알부민을 함유하는 유중수형 피부 개선용 화장료 조성물에 관한 것으로, 본 발명의 화장료 조성물은 세포배양배지 및 알부민을 포함하면서도 제형의 안정성을 제공함으로써, 부드럽게 펴발리며 흡수 후 끈적임 없이 영양감을 부여할 수 있는 피부 개선용 화장료 조성물의 용도로 유용하게 사용될 수 있다. The present invention relates to a water-in-oil type skin improvement cosmetic composition containing a cell culture medium and albumin. The cosmetic composition of the present invention provides stability of the formulation while containing a cell culture medium and albumin, and thus can be usefully used as a skin improvement cosmetic composition that can be smoothly spread and provides a feeling of nutrition without being sticky after absorption.
이하 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.The present invention will be described in more detail through the following examples. However, these examples are provided for illustrative purposes only and the scope of the present invention is not limited to these examples.
비교예 1: 세포배양배지 및 알부민을 포함하는 조성물의 제조Comparative Example 1: Preparation of a composition containing cell culture medium and albumin
하기 표 1에 기재된 세포배양배지의 성분 및 알부민을 용매(예를 들어, 정제수 등)에 충분히 용해시켜 모든 성분들이 녹은 것을 확인한 뒤, 0.2 ㎛ 여과기로 여과하여, 하기 23종의 구성성분을 포함하는 혼합 조성물을 제조하였다. 하기 표 1에 기재된 각 구성성분은 모두 시그마-알드리치(Sigma-Aldrich, USA)에서 구입하였으며, 하기 표 1에 기재된 23종의 성분의 조합을 이하 SPM이라고 표기한다.The components of the cell culture medium and albumin described in Table 1 below were sufficiently dissolved in a solvent (e.g., purified water, etc.) to confirm that all components were dissolved, and then filtered through a 0.2 ㎛ filter to prepare a mixed composition containing the following 23 components. Each component described in Table 1 below was purchased from Sigma-Aldrich (Sigma-Aldrich, USA), and the combination of the 23 components described in Table 1 below is referred to as SPM hereinafter.
한편, 표 1에 기재된 농도는 상기 구성성분이 용매에 완전히 용해된 경우 용액에서의 최종 농도를 의미한다.Meanwhile, the concentrations listed in Table 1 refer to the final concentrations in the solution when the above components are completely dissolved in the solvent.
(thiamine hydrochloride)Thiamine hydrochloride
(thiamine hydrochloride)
(Niacinamide)Niacinamide
(Niacinamide)
(pyridoxine hydrochloride)Pyridoxine hydrochloride
(pyridoxine hydrochloride)
제조예 2: 세포배양배지 및 알부민을 포함하는 유중수형 화장료 조성물의 제조Manufacturing Example 2: Manufacturing of a water-in-oil type cosmetic composition containing cell culture medium and albumin
세포배양배지 및 알부민을 포함하는 유중수형 화장료 조성물을 제조하기 위해, 하기와 같은 실험을 수행하였다.To prepare a water-in-oil type cosmetic composition containing a cell culture medium and albumin, the following experiments were performed.
구체적으로, 하기 표 2 내지 표 4에 나타낸 함량비에 따라 유상부를 비이커에 개량한 후, 호모믹서(Homo Mixer)를 이용하여 75℃에서 2500rpm으로 5분간 교반하여 완전히 용해된 것을 확인하였다. 다음으로, 용해된 수상부를 유상부에 천천히 첨가하면서 6500rpm으로 5분간 교반 후 최종 30℃까지 냉각하여 화장료 조성물을 제조하였다. Specifically, the oil phase was added to a beaker according to the content ratios shown in Tables 2 to 4 below, and then stirred at 2,500 rpm at 75°C for 5 minutes using a homomixer to confirm complete dissolution. Next, the dissolved water phase was slowly added to the oil phase while stirring at 6,500 rpm for 5 minutes, and then cooled to 30°C to prepare a cosmetic composition.
한편, 하기 표 2는 계면활성제 변화에 의한 화장료 조성물을 제조한 것이고, 하기 표 3은 점증제(안정화제) 변화에 의한 화장료 조성물을 제조한 것이고, 표 4는 왁스 변화에 의한 화장료 조성물을 제조한 것이다.Meanwhile, Table 2 below shows cosmetic compositions prepared by changing the surfactant, Table 3 below shows cosmetic compositions prepared by changing the thickener (stabilizer), and Table 4 below shows cosmetic compositions prepared by changing the wax.
실험예 1: 화장료 제형의 온도 변화에 따른 안정성 시험 Experimental Example 1: Stability Test of Cosmetic Formulation According to Temperature Change
본 발명의 유중수형 화장료 제형의 온도 변화에 따른 안정성을 확인하기 위해, 하기와 같은 실험을 수행하였다.In order to confirm the stability of the water-in-oil type cosmetic formulation of the present invention according to temperature change, the following experiment was conducted.
구체적으로, 상기 비교예 1 내지 3과 실시예 1 내지 12의 화장료 제형에 대하여 4 ℃, 45 ℃, 50 ℃, Cycle(-15℃~45℃)의 항온조 및 실온에서 1주일, 1개월 및 6개월을 단위로 하여 장기 보전 안정성을 하기의 평가 기준으로 평가하였으며, 그 결과를 하기 표 5 내지 표 7에 나타내었다 (평가기준, 안정: ○, 불안정: △, 분리: ×).Specifically, the long-term storage stability of the cosmetic formulations of Comparative Examples 1 to 3 and Examples 1 to 12 was evaluated based on the evaluation criteria below in a constant temperature bath of 4°C, 45°C, and 50°C, in a cycle (-15°C to 45°C), and at room temperature for 1 week, 1 month, and 6 months, and the results are shown in Tables 5 to 7 below (evaluation criteria, stable: ○, unstable: △, separated: ×).
(-15~45℃)Cycle
(-15~45℃)
(-15~45℃)Cycle
(-15~45℃)
(-15~45℃)Cycle
(-15~45℃)
상기 표 5 내지 표 7에 나타난 바와 같이, 계면활성제, 점증제(안정화제) 또는 왁스를 사용하지 않은 비교예 1 내지 3의 제형은 불안정하였으나, 실시예 1 내지 12의 경우 안정성이 우수한 것을 확인하였다. 상기 결과를 토대로, 본 발명의 세포배양배지 및 알부민을 포함하는 유중수형 제형의 경우, 제형의 유효성분에 의해서는 안정성에 문제가 없음을 알 수 있다.As shown in Tables 5 to 7 above, the formulations of Comparative Examples 1 to 3 that did not use a surfactant, thickener (stabilizer), or wax were unstable, but those of Examples 1 to 12 were found to have excellent stability. Based on the above results, it can be seen that there is no problem with the stability of the water-in-oil formulation containing the cell culture medium and albumin of the present invention due to the effective ingredient of the formulation.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The above description of the present invention is for illustrative purposes only, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential characteristics of the present invention. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive.
Claims (18)
상기 아미노산 성분은 아미노산인 세린 1 중량부를 기준으로 0.2 내지 1.2 중량부의 글리신, 0.08 내지 0.3 중량부의 L-알라닌, 2 내지 7 중량부의 L-아르기닌 하이드로클로라이드, 0.2 내지 0.9 중량부의 L-시스테인 하이드로클로라이드-모노하이드레이트, 10 내지 18 중량부의 L-글루타민, 0.8 내지 2.0 중량의 L-히스티딘 하이드로클로라이드-모노하이드레이트, 1.0 내지 5.0 중량부의 L-라이신 하이드로클로라이드, 0.2 내지 1.2 중량부의 L-메티오닌, 0.2 내지 1.2 중량부의 L-프롤린, 1 중량부의 L-세린, 1.0 내지 5.0 중량부의 L-트레오닌 및 1.0 내지 5.0 중량부의 L-발린을 포함하고,
상기 비타민 성분은 i-이노시톨, 티아민 하이드로클로라이드, 나이아신아마이드 및 피리독신 하이드로클로라이드를 포함하고,
상기 무기염 성분은 염화나트륨(NaCl), 탄산수소나트륨(NaHCO3), 염화칼륨(KCl), 염화칼슘(CaCl2)(무수) 및 인산수소나트륨 모노하이드레이트(NaH2PO4-H2O)를 포함하고,
상기 기타 성분은 소듐 피루베이트를 포함하는 것인, 조성물.In claim 1, the cell culture medium contains amino acid components, vitamin components, mineral salt components, and other components.
The amino acid component comprises, based on 1 part by weight of the amino acid serine, 0.2 to 1.2 parts by weight of glycine, 0.08 to 0.3 parts by weight of L-alanine, 2 to 7 parts by weight of L-arginine hydrochloride, 0.2 to 0.9 parts by weight of L-cysteine hydrochloride-monohydrate, 10 to 18 parts by weight of L-glutamine, 0.8 to 2.0 parts by weight of L-histidine hydrochloride-monohydrate, 1.0 to 5.0 parts by weight of L-lysine hydrochloride, 0.2 to 1.2 parts by weight of L-methionine, 0.2 to 1.2 parts by weight of L-proline, 1 part by weight of L-serine, 1.0 to 5.0 parts by weight of L-threonine, and 1.0 to 5.0 parts by weight of L-valine,
The above vitamin ingredients include i-inositol, thiamine hydrochloride, niacinamide and pyridoxine hydrochloride.
The above inorganic salt components include sodium chloride (NaCl), sodium bicarbonate (NaHCO 3 ), potassium chloride (KCl), calcium chloride (CaCl 2 ) (anhydrous), and sodium biphosphate monohydrate (NaH 2 PO 4 -H 2 O).
A composition wherein the other ingredients include sodium pyruvate.
A water-in-oil type external skin preparation composition comprising a cell culture medium and albumin.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230085992A KR20250006404A (en) | 2023-07-03 | 2023-07-03 | A water-in-oil cosmetic composition comprising cell culture medium and albumin and use thereof |
PCT/KR2024/006143 WO2024232642A1 (en) | 2023-05-09 | 2024-05-08 | Cosmetic composition comprising cell culture medium and albumin, and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230085992A KR20250006404A (en) | 2023-07-03 | 2023-07-03 | A water-in-oil cosmetic composition comprising cell culture medium and albumin and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20250006404A true KR20250006404A (en) | 2025-01-13 |
Family
ID=94242767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230085992A Pending KR20250006404A (en) | 2023-05-09 | 2023-07-03 | A water-in-oil cosmetic composition comprising cell culture medium and albumin and use thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20250006404A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102368465B1 (en) | 2016-04-01 | 2022-03-02 | 주식회사 바이오코즈글로벌코리아 | Cosmetic composition comprising albumin, hyaluronic acid, or collagen in cell culture medium |
-
2023
- 2023-07-03 KR KR1020230085992A patent/KR20250006404A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102368465B1 (en) | 2016-04-01 | 2022-03-02 | 주식회사 바이오코즈글로벌코리아 | Cosmetic composition comprising albumin, hyaluronic acid, or collagen in cell culture medium |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100952109B1 (en) | Personal Care Compositions Containing Dipeptides | |
US20240285509A1 (en) | Redness correcting skin care formulations | |
ES2668072T3 (en) | Cutaneous metabolic bioactivator | |
US20050266064A1 (en) | Cosmetic compositions and methods | |
JP2011516585A (en) | Skin care composition and method of use thereof | |
JPWO2004016236A1 (en) | Cosmetics | |
JP2013540766A (en) | Cosmetic skin care composition | |
US20090004280A1 (en) | kit for caring for the skin intended to soften cutaneous signs of ageing | |
JP3863675B2 (en) | Topical skin preparation | |
JP2001511185A (en) | Skin lightning composition | |
US20080160088A1 (en) | Composition containing hydroxyapatite and a calcium salt | |
PL214285B1 (en) | Use of purslane to treat facial wrinkles | |
KR102187653B1 (en) | Freeze dried cosmetics for skin improvement | |
JP3908126B2 (en) | Epidermal keratinization normalizing agent and skin external preparation containing the same | |
JP2005239645A (en) | Composition for promoting collagen synthesis | |
KR102479550B1 (en) | Skin elasticity improvement cosmetics and manufacturing method thereof | |
JP5455292B2 (en) | Skin external composition | |
JP4594580B2 (en) | Protein carbonylation inhibitor, skin external preparation and method | |
JP2020033346A (en) | Topical composition comprising Pichia anomara and N-acetylglucosamine | |
KR20250006404A (en) | A water-in-oil cosmetic composition comprising cell culture medium and albumin and use thereof | |
KR20250006403A (en) | A oil-in-water cosmetic composition comprising cell culture medium and albumin and use thereof | |
JP2005263794A (en) | Collagen synthesis acceleration composition | |
KR102267938B1 (en) | Moisturizing cosmetics that improve skin absorption, including asiatic pennywort extract, anemarrhena asphodeloides root extract, apricot seed oil, and peptides having antioxidant activity, and a method for manufacturing the same | |
KR20210117375A (en) | Cream capsule-gel formulation having a three-dimensional solid shape to which a 3d printing method is applied and a manufacturing method thereof | |
JP4608691B2 (en) | Protein carbonylation inhibitor, skin external preparation and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20230703 |
|
PG1501 | Laying open of application |